// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Identification of unique grass species peptides, in a thirteen grass species aqueous extract sample by LC‐MS/MS

Bell A - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Clinical and immunological changes after 1‐year treatment with a tyrosine‐adsorbed mite allergoid: D. Pteronyssinus 50% + D. Farinae 50%

De La Roca Pinzon F - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

L-Tyrosine

An adjuvant systems approach to develop vaccines against challenging diseases: Dioleoyl phosphatidylserine (DOPS) confers enhanced protection against malaria for VLP‐TRAP based vaccines

Heath - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Malaria

Phosphatidylserine

Development of a total antigenicity IgG ELISA for the quality control of a mixed grass allergoid drug product

Starchenka S - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Promethazine anaphylaxis: A case report

Yung SCC - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anaphylaxis

Dextromethorphan

Outcomes of patients undergoing nasal aspirin desensitisation for aspirin exacerbated respiratory disease at lancashire teaching hospitals, a tertiary adult allergy centre in the UK

Anantharachagan A - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Aspirin

Effectiveness and safety of a modified Dermatophagoides Pteronyssinus allergoid, associated with microcrystalline tyrosine, in adult patients with allergic rhinitis, with or without asthma

Roger A - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

L-Tyrosine

Results of immunotherapy with a polymerized extract associated with microcrystalline tyrosine, in patients with allergic asthma caused by the house dust mite dermatophagoides

Padr C - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

L-Tyrosine

Health and satisfaction results reported by patients, after a treatment based on a modified dermatophagoides pteronyssinus extract associated with microcrystalline tyrosine (MCT)

Malet A - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

L-Tyrosine

The health and economic impact of allergen therapy in patients with allergic rhinoconjunctivitis: Real‐world evidence from the Czech Republic

Strosova D - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Grass pollen sublingual immunotherapy – experience in a UK children's hospital

Sismanoglou N - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

No correlation between conjunctival provocation test and immune globulins in a positive phase II allergen immunotherapy study with subcutaneously administered tyrosine adsorbed modified grass allergen

Zielen S - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

L-Tyrosine

Strong dose‐response on immunoglobulin markers during a phase II allergen immunotherapy study with subcutaneously administered tyrosine adsorbed modified grass allergen + MPL

Zielen S - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

L-Tyrosine

Results of scit with a polymerised extract, associated with microcrystalline tyrosine, in allergic patients to dermatophagoides Spp. According to their sensitization profile to Der p1 and Der p2

Moreno F - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

L-Tyrosine

A two‐site immunoassay for the quantification of lolium perenne grass pollen allergen, Lol P 1

Bermingham M - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The lived experience of nasal polyps – the current understanding of the patients’ perspective

Hall R - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Novel patient centric approach to understand the patient experience of nasal polyps

Hall R - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Successful intravaginal graded human seminal plasma desensitization in a Can F5 sensitized patient

Vil-Nadal G - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

Human serum albumin

Efficacy of omalizumab in hereditary alpha tryptasaemia

Dziadzio M - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Prednisolone

International severe asthma registry (ISAR): Mission statement

Canonica GW - European Academy of Allergy and Clinical Immunology (EAACI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Copyright © 2026. QuantiNova All rights reserved